Arena Pharmaceuticals, Inc. (ARNA) belonging to the Medical sector has declined -1.87% and closed its last trading session at $1.57.
The company reported its EPS on 03/14/2017. Currently, the stock has a 1 Year Price Target of $4.5.
The consensus recommendation, according to Zacks Investment research, is 2. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 2 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2 and 2.4 respectively.
Arena Pharmaceuticals, Inc. on 03/14/2017 reported its EPS as $0.26 with the analysts projecting the EPS of the stock as $-0.08. The company beat the analyst EPS Estimate with the difference of $0.34. This shows a surprise factor of 425%.
Many analysts have provided their estimated foresights on Arena Pharmaceuticals, Inc. Earnings, with 4 analysts believing the company would generate an Average Estimate of $-0.09.
Whereas they predicted High and Low Earnings Estimate as $-0.07 and $-0.1 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.09.
Analysts are also projecting an Average Revenue Estimate for Arena Pharmaceuticals, Inc. as $5.37 Million in the Current Quarter. This estimate is provided by 3 analysts.
The High Revenue estimate is predicted as 8.5 Million, while the Low Revenue Estimate prediction stands at 3 Million. The company’s last year sales total was 9.85 Million.
For the Current Quarter, the growth estimate for Arena Pharmaceuticals, Inc. is 0%, while for the Next Quarter the stock growth estimate is 18.2%.
The Company got Initiated by FBR & Co. on 15-Sep-16 to Outperform.
Insider Trades for Arena Pharmaceuticals, Inc. show that the latest trade was made on 29 Dec 2016 where Munshi Amit, the Chief Executive Officer completed a transaction type “Buy” in which 625 shares were traded at a price of $1.21.
3 analysts projected Price Targets for Arena Pharmaceuticals, Inc.. The analysts believe that the company stock price could grow as high as $6. The Low Price target projection by analysts is $3.5 and the Mean Price Target is $4.5.
Arena Pharmaceuticals, Inc. (ARNA) has the market capitalization of $381.91 Million. The company rocked its 52-Week High of $2.16 on Jun 9, 2016 and touched its 52-Week Low of $1.34 on Jan 20, 2017.
The stock has Return on Assets (ROA) of -39.5 percent. Return on Equity (ROE) stands at -339.1% and Return on Investment (ROI) of -84.7 percent.
The stock is currently showing YTD performance of 10.56 Percent. The company has Beta Value of -0.96 and ATR value of 0.08. The Weekly and Monthly Volatility stands at 5.24% and 4.91%.